Abstract:Background There is increasing interest in the role of brain-derived neurotrophic factor (BDNF) in the onset and course of schizophrenia, but there are conflicting reports about serum levels of BDNF in patients with schizophrenia. Aim Conduct a meta-analysis combining studies from China and other countries that have evaluated the relationship of serum BDNF levels to schizophrenia. Method We used Cochrane methodology and RevMan 5.1 software to identify and pool the results of studies. Electronic searches of western and Chinese registries and follow-up assessment of references located 268 potential articles. Twenty-five articles (20 in English and 5 in Chinese) published before December 2011 that used case-control methods, included patients with schizophrenia who had no concurrent disorders, and used ELISA technology to assess serum BDNF were included in the analysis. The main outcome was the pooled standardized mean difference (SMD) between cases and controls. The quality of the studies was independently assessed by two raters using the GRADE system. The heterogeneity, sensitivity and potential publication bias of the studies was evaluated using RevMan. Results The pooled sample included 1663 patients with schizophrenia and 1355 controls. Fifteen of the included studies were rated as ‘poor quality’ and 10 were rated as ‘very poor quality’. The results of the studies were quite heterogenous (I2=95%) but subgroup analyses found that the heterogeneity was not related to country of origin, sample size, age, gender, prior use of antipsychotic medication, or study quality. The pooled SMD (computed using a random-effect model because of study heterogeneity) was -0.74 (95% CI, -0.99∼-0.50; Z=5.99, p<0.001). Sensitivity analysis found that the result was stable and there was no evidence of publication bias. Conclusion Despite the robust statistical findings of lower serum BDNF in patients with schizophrenia than in controls, given the low quality of the available studies and the substantial heterogeneity between studies, the evidence of lower serum BDNF in patients with schizophrenia must be considered ‘weak’. The potential use of serum BDNF as a biomarker for schizophrenia must wait until higher-quality prospective studies that follow patients over time and that use uniform selection and monitoring procedures confirm these preliminary results.

Serum Levels of Brain-Derived Neurotrophic Factor Are Associated with Depressive Symptoms in Patients with Systemic Lupus Erythematosus

Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia

An Analysis of Serum Levels of BDNF and Relative Factors in Depressive Patients

Peripheral Blood Brain-Derived Neurotrophic Factor Level and Tyrosine Kinase B Expression on T Lymphocytes in Systemic Lupus Erythematosus: Implications for Systemic Involvement

Association of Anhedonia with Brain-Derived Neurotrophic Factor and Interleukin-10 in Major Depressive Disorder

The Relationship between Level of BDNF in Serum and Depressive Symptoms and Cognitive Dysfunction of Patients with Major Depression

747 – Brain-derived Neurotrophic Factor and B-Cell Lymphoma Leukemia-2 Plasma Levels in Patients with Subsyndromal Symptomatic Depression

Low BDNF Levels in Serum Are Associated with Cognitive Impairments in Medication-Naïve Patients with Current Depressive Episode in BD II and MDD.

Serum Brain-derived Neurotrophic Factor Levels in Post-Stroke Depression.

Brain-derived neurotrophic factor (BDNF) serum level in women with first-episode depression, correlation with clinical and metabolic parameters

Peripheral Blood BDNF-TrkB Signaling in First-Episode, Drug-Free Patients with Major Depressive Disorder and Schizophrenia.

Relationship between serum BDNF level and Parkinson disease depression

The Level of Serum Brain-Derived Neurotrophic Factor is Associated with the Therapeutic Efficacy of Modified Electroconvulsive Therapy in Chinese Patients with Depression

The association between levels of brain‐derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study

Cross-sectional study of the association between serum concentration of brain-derived neurotrophic factor and bipolar disorder

Serum brain derived neurotrophic factor levels and post-stroke depression in ischemic stroke patients

Brain-derived Neurotrophic Factor Expression in Peripheral Leukocytes of Patients with Subsyndromal Symptomatic Depression

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients

Serum Levels of FGF21, β-Klotho, and BDNF in Stable Coronary Artery Disease Patients With Depressive Symptoms: A Cross-Sectional Single-Center Study

Depressive Symptoms in Schizophrenia Patients: A Possible Relationship Between SIRT1 and BDNF.

Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Schizophrenia: A Systematic Review